docetaxel + gemcitabine + pemetrexed

This is a combination chemotherapy regimen consisting of three cytotoxic agents—docetaxel, gemcitabine, and pemetrexed. Each drug has a distinct mechanism of action targeting cancer cell proliferation: - Docetaxel is a semisynthetic taxane that stabilizes microtubules, preventing their depolymerization. This leads to cell cycle arrest at the G2/M phase and induces apoptosis in rapidly dividing cells. - Gemcitabine is a nucleoside analog (difluorinated deoxycytidine) that incorporates into DNA during replication after intracellular phosphorylation. It inhibits DNA synthesis by reducing deoxynucleotide pools and causing chain termination. - Pemetrexed is an antifolate agent that inhibits multiple enzymes involved in folate metabolism and DNA synthesis (including thymidylate synthase), thereby blocking purine and pyrimidine biosynthesis. These drugs are individually approved for various solid tumors such as non-small cell lung cancer (NSCLC), mesothelioma, sarcomas, among others. While two-drug combinations involving these agents are established in clinical practice for NSCLC or sarcoma, the triple combination of docetaxel + gemcitabine + pemetrexed does not have established approval or widespread use due to concerns about cumulative toxicity[1][2][3]. The rationale for combining them would be to exploit potential additive or synergistic antitumor effects by targeting different pathways critical for tumor growth.

Other names

docetaxel and gemcitabine and pemetrexeddocetaxel plus gemcitabine plus pemetrexed